Clinical Trial
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Study acronym: PETITE-T1D
Active, Not Recruiting
Phase 4
View on ClinicalTrials.gov →
The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are \<8 years of age.
| NCT Number |
NCT05757713 |
| Lead Sponsor |
Sanofi
|
| Conditions |
Diabetes Mellitus, Type 1 |
| Enrollment |
20 participants |
| Start Date |
2023-07-25 |
| Primary Completion |
2026-08-27 (estimated) |
| Study Completion |
2026-08-27 (estimated) |
| Updated on ClinicalTrials.gov |
2026-01-30 |